The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
Fred Hutchinson Cancer Research Center investigators engineered T cells to recognize a protein expressed by acute myeloid leukemia cells with a CBFB-MYH11 gene fusion.
The global license extends to all indications under evaluation, though Rain will focus on exploring the activity of milademetan in MDM2-amplified or -overexpressing cancers.
Awaiting data from the Phase II SOLAR trial, miRagen is looking to potentially advance cobomarsen into registration-enabling studies for miR-155 elevated CTCL and ATLL.
The agreement will facilitate key proof-of-concept studies for Hemogenyx's HEMO-CAR-T product in AML, where there is an unmet need for new safe and effective treatments.
Chi-Med subsidiary Hutchison Medipharma has kicked off the Phase I trial in China and has dosed its first patient with the investigational IDH inhibitor.
